XGN News and Press, Exagen Inc. From 11/04/25

2025-11-04 15:57:15 ET More on Exagen Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now Exagen GAAP EPS of -$0.31 misses by $0.15, revenue of $17.24M beats by $0.34M Seeking Alpha’s...

2025-11-04 08:09:31 ET More on Exagen Exagen's Momentum Meets Execution Risks: Why I Choose To HOLD For Now Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen Read the full article on S...

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates. Q3 2025 Highlights and Recent Corporate Updates: ...

Advanced Energy Industries Inc. (AEIS) is expected to report $1.16 for Q3 2025 Neuropace Inc. (NPCE) is expected to report $-0.2 for Q3 2025 Oportun Financial Corporation (OPRT) is expected to report $0.2 for Q3 2025 trivago N.V. (TRVG) is expected to report $0.07 for Q3 2025 Alle...

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025...

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President...

2025-09-13 08:29:57 ET Exagen Inc. ( XGN ) stock is having an excellent year, now trading at its 52-week highs, levels last attained during the beginning of January 2022. XGN stock had a rough and very slow patch from October 2022 to July 2024, and now it looks like it's back on tra...

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45 th Annual Growth Co...

2025-07-29 15:10:18 ET More on Exagen Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript Exagen Inc. (XGN) Q1 2025 Earnings Call Transcript Exagen GAAP EPS of -$0.21 misses by $0.06, revenue of $17.2M beats by $0.89M Exagen prices public offering of common st...

2025-07-29 15:09:37 ET Exagen Inc. (XGN) Q2 2025 Earnings Conference Call July 29, 2025, 08:30 AM ET Company Participants Jeffrey G. Black - CFO & Corporate Secretary John Aballi - CEO, President & Director Ryan Douglas - Investors Relations Officer ...